Skip to content
DataLookout
Menu

ATTRACTNCT07732309

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 1, 2026 to Sep 26, 2026
    • Site details revised at 22 of 22 sites
  2. Notable Eligibility criteria shortened, about 18 words
    • Site details revised at 4 of 22 sites
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and TolerabilitySafety and Tolerability
Timeframe: 48 weeks

Arms and interventions

ATG-201Experimental

This is a phase I, open-label, first-in-human clinical trial to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of ATG-201 in participants with autoimmune diseases. The study will be conducted in 2 parts: Dose Escalation (Part I) and Dose Expansion (Part II). Part I (Dose Escalation) A total of 9 dose levels is preset In Part II (Dose Expansion), the OBD(s) will be further explored and evaluated

Drugs: ATG-201

Sites

22 sites in 1 country